Exagen Analyst Ratings
Exagen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 132.11% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 05/16/2023 | 132.11% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 03/22/2023 | 93.42% | BTIG | $6 → $5 | Maintains | Buy |
| 11/17/2022 | 170.79% | BTIG | $10 → $7 | Maintains | Buy |
| 11/15/2022 | 170.79% | Canaccord Genuity | $8 → $7 | Maintains | Buy |
| 05/13/2022 | 557.64% | Keybanc | $20 → $17 | Maintains | Overweight |
| 03/25/2022 | 673.69% | Keybanc | $30 → $20 | Maintains | Overweight |
| 11/11/2021 | 1060.54% | Keybanc | $33 → $30 | Maintains | Overweight |
| 04/15/2021 | 867.12% | Canaccord Genuity | → $25 | Initiates Coverage On | → Buy |
| 03/02/2021 | 1176.6% | KeyBanc | $32 → $33 | Maintains | Overweight |
| 11/10/2020 | 1137.91% | Keybanc | → $32 | Initiates Coverage On | → Overweight |
| 10/08/2020 | 596.32% | BTIG | → $18 | Initiates Coverage On | → Buy |
| 06/02/2020 | 673.69% | Cantor Fitzgerald | $19 → $20 | Assumes | → Overweight |
| 11/13/2019 | 867.12% | Cantor Fitzgerald | $18 → $25 | Maintains | Overweight |
| 10/14/2019 | 596.32% | Cantor Fitzgerald | → $18 | Initiates Coverage On | → Overweight |
| 10/14/2019 | 557.64% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 10/14/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月22日 | 132.11% | 康託·菲茨傑拉德 | →$6 | 重申 | 超重→超重 |
| 2023年05月16日 | 132.11% | 康託·菲茨傑拉德 | →$6 | 重申 | 超重→超重 |
| 03/22/2023 | 93.42% | BTIG | $6→$5 | 維護 | 買 |
| 2022年11月17日 | 170.79% | BTIG | $10→$7 | 維護 | 買 |
| 2022年11月15日 | 170.79% | 卡納科特·格納奇 | $8→$7 | 維護 | 買 |
| 2022年05月13日 | 557.64% | KeyBanc | $20→$17 | 維護 | 超重 |
| 03/25/2022 | 673.69% | KeyBanc | $30→$20 | 維護 | 超重 |
| 2021年11月11日 | 1060.54% | KeyBanc | $33→$30 | 維護 | 超重 |
| 04/15/2021 | 867.12% | 卡納科特·格納奇 | →$25 | 開始承保 | →購買 |
| 03/02/2021 | 1176.6% | KeyBanc | $32→$33 | 維護 | 超重 |
| 11/10/2020 | 1137.91% | KeyBanc | →$32 | 開始承保 | →超重 |
| 10/08/2020 | 596.32% | BTIG | →$18 | 開始承保 | →購買 |
| 06/02/2020 | 673.69% | 康託·菲茨傑拉德 | $19→$20 | 假設 | →超重 |
| 2019年11月13日 | 867.12% | 康託·菲茨傑拉德 | $18→$25 | 維護 | 超重 |
| 2019年10月14日 | 596.32% | 康託·菲茨傑拉德 | →$18 | 開始承保 | →超重 |
| 2019年10月14日 | 557.64% | 考恩公司 | →$17 | 開始承保 | →跑贏大盤 |
| 2019年10月14日 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 |
What is the target price for Exagen (XGN)?
埃克森美孚的目標價是多少？
The latest price target for Exagen (NASDAQ: XGN) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $6.00 expecting XGN to rise to within 12 months (a possible 132.11% upside). 5 analyst firms have reported ratings in the last year.
康託·菲茨傑拉德於2023年8月22日報道了埃克森(納斯達克：XGN)的最新目標價。這家分析公司將目標價定為6美元，預計XGN將在12個月內上漲至(可能上漲132.11%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Exagen (XGN)?
分析師對埃克森美孚的最新評級是多少？
The latest analyst rating for Exagen (NASDAQ: XGN) was provided by Cantor Fitzgerald, and Exagen reiterated their overweight rating.
分析師對埃克森美孚(納斯達克股票代碼：XGN)的最新評級由康託·菲茨傑拉德提供，埃克森美孚重申其增持評級。
When is the next analyst rating going to be posted or updated for Exagen (XGN)?
Exagen(XGN)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exagen was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Exagen的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Exagen的上一次評級是在2023年8月22日提交的，所以你應該預計下一次評級將在2024年8月22日左右提供。
Is the Analyst Rating Exagen (XGN) correct?
分析師評級Exagen(XGN)正確嗎？
While ratings are subjective and will change, the latest Exagen (XGN) rating was a reiterated with a price target of $0.00 to $6.00. The current price Exagen (XGN) is trading at is $2.59, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Exagen(XGN)評級被重申，目標價在0.00美元至6.00美元之間。埃克森美孚目前的交易價格為2.59美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。